Abstract

The hallmark of hematopoietic stem cells (HSCs) is their ability to self-renew and differentiate into multiple blood cell types. Transplantation of human HSCs into immunocompromised mice is the gold standard for evaluating functionality and has been adapted to study leukemia initiating cells (LICs). However, specific cellular subsets do not survive post-xenotransplantation, due to a dependence on factors that may be missing in a non-primate microenvironment.

We have been optimizing the zebrafish as a xenograft platform. We created novel zebrafish that express human stem cell factor (SCF/KITLG), granulocyte-macrophage colony stimulating factor (GM-CSF/CSF2) and stromal cell-derived factor 1 alpha (SDF1α/CXCL12) - factors essential for survival and expansion of HSCs.

CMK (Down Syndrome- acute myeloid leukemia (AML)) and Jurkat (T-cell acute lymphoblastic leukemia) cell lines injected into the yolk sac of these multi-cytokine zebrafish larvae exhibit increased proliferation and migration to hematopoietic niches, namely the caudal hematopoietic tissue (=fetal liver) at 7 days post-injection (dpi) and the kidney marrow at 11 dpi, compared to injections in control casper larvae.

Patient-derived AML bone marrow samples (n=3) injected into the circulation of these multi-cytokine fish similarly displayed enhanced proliferation and migration with associated larval mortality from increased disease burden. Historically, human HSCs do not survive beyond 24 hpi in zebrafish xenografts (Pruvot et al. 2011). Remarkably, human umbilical cord blood-derived HSCs injected into the circulation of zebrafish larvae survived past three days-post-injection in multi-cytokine fish but not in casper controls.

Transgenic zebrafish expressing human cytokines provide an enhanced model for studying human leukemia and HSC biology in a system that more closely recapitulates the human microenvironment. By employing these humanized zebrafish and exploiting the inherent capacity of this small organism for rapid chemical screening, we have created a new preclinical paradigm for testing anti-leukemic therapies and HSC enhancing agents.

Disclosures

No relevant conflicts of interest to declare.

Author notes

*

Asterisk with author names denotes non-ASH members.